Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Condition: Metastatic Non-Small Cell Lung Cancer Interventions: Biological: Pembrolizumab; Drug: Lenvatinib; Drug: Docetaxel Sponsors: Merck Sharp & Dohme Corp.; Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Taxotere